Peroral Levosimendan in Chronic Heart Failure

Summary

The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at least 6 months.

Timeline

Start

2005-03

Primary completion

—

Completion

2006-03

Drugs

Indications